Claire M. Steppan, Ph.D. is a Research Fellow in Pfizer’s Primary Pharmacology group within Discovery Sciences and has played an integral role in establishing Pfizer’s enabling SLC platform. Claire is an accomplished pharmacologist with scientific leadership spanning from early discovery through clinical development in diabetes, obesity, Alzheimer’s disease, pain, gout, peripheral artery disease, depression and COVID-19. Within Pfizer, she has been the research project leader for multi-disciplinary teams that produced two FIH starts and one Phase 2 start for the treatment of Type 2 diabetes. She has a long-standing interest in SLC transporters beginning with Pfizer’s SGLT2 inhibitor, ertugliflozin.  Both within Pfizer and the scientific community, she is committed to unlocking the potential of Solute Carriers as drug targets for the treatment of human disease.